This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-08. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
=== Political donations (2018) === In 2018, In-N-Out faced calls for boycott after donating $25,000 to the California GOP ahead of the November elections, as well as $30,000 in August 2017 and another $30,000 in May 2016.
Notch proteins are a family of type 1 transmembrane proteins that form a core component of the Notch signaling pathway, which is highly conserved in animals. The Notch extracellular domain mediates interactions with DSL family ligands, allowing it to participate in juxtacrine signaling. The Notch intracellular domain acts as a transcriptional activator when in complex with CSL family transcription factors. Members of this type 1 transmembrane protein family share several core structures, including an extracellular domain consisting of multiple epidermal growth factor (EGF)-like repeats and an intracellular domain transcriptional activation domain (TAD). Notch family members operate in a variety of different tissues and play a role in a variety of developmental processes by controlling cell fate decisions. Much of what is known about Notch function comes from studies done in Caenorhabditis elegans (C. elegans) and Drosophila melanogaster. Human homologs have also been identified, but details of Notch function and interactions with its ligands are not well known in this context.
fractional distillation The fractionation of a mixture of liquids into its component parts, or fractions, by the process of distillation, typically by using a long vertical column attached to the distillation vessel and filled with glass beads. The mixture is heated to a temperature at which one or more of the component compounds will vaporize; the vapor rises up the column until it condenses and runs back into the vessel, creating a temperature and volatility gradient and permitting various fractions to be drawn off at different points along the length of the column. Common in industrial chemistry, the technique is sensitive enough to separate compounds which have boiling points that differ by less than 25 °C (45 °F) from each other at standard pressure.
Sources: en.wikipedia.org
== Computational methods == Most PPI methods require some computational data analysis. The methods in this section are primarily computational although they typically require data generated by wet lab experiments. Protein–protein docking, the prediction of protein–protein interactions based only on the three-dimensional protein structures from X-ray diffraction of protein crystals might not be satisfactory. Network analysis includes the analysis of interaction networks using methods of graph theory or statistical methods. The goal of these studies is to understand the nature of interactions in the context of a cell or pathway, not just individual interactions.
It is important to mention that ESR studies were also performed that show a coexistence of the liquid-order/liquid-disorder phase from 0 to 8 mole% and as well as 8–27 mol%. The model membrane containing DPPC, cholesterol, and exchanging lipids 1 and 2 show a drastic increase in the linear relationship between (K) versus the mol% of cholesterol. At approximately 8 mol% of cholesterol the start of the liquid-disordered phase begins. This same relationship is observed in the DSPC, cholesterol, and exchanging lipids 2 and 3 but the start of the liquid-disorder phase occurs at approximately 5.2 mole% with and without the presence of ethanol. Also, there is a higher equilibrium constant value in which the studies relate it to the stronger acyl chain interactions due to this region having longer carbon chains which results in a higher melting point as well. This study not only proves that in the presence of ethanol a reorganization or induced phase change takes place between the cholesterol-phospholipid interaction but that by using higher concentrations of sterol compounds like cholesterol it can hinder the effects of ethanol. The research also suggests that ethanol enhances the association between cholesterol-phospholipids within the liquid-ordered bilayers. The mechanism on how ethanol induces the liquid-disorder phase as well as enhances the cholesterol-phospholipid association is still not understood.
== Energy sources == Unlike proto-metabolism, the bioenergetic pathways powering modern metabolism are well understood. In early Earth conditions, there were mainly three kinds of energy to support early metabolic pathways: high energy sources to catalyze monomers, lower energy sources to support condensation or polymerization, and energy carriers that support transfer of energy from the environment to metabolic networks. Examples of high energy sources include photochemical energy from ultraviolet light, atmospheric electric discharge, and geological electrochemical energy. These energy sources would support synthesis of biological monomers or feedstocks for proto-metabolism. In contrast, examples of lower energy sources for assembly of more complex molecules include anhydrous heat, mineral-catalyzed synthesis, and sugar-driven reactions. Energy carrier molecules could allow for propagation of the energy through the metabolic networks likely resembled modern energy carriers including ATP and NADH. Both energy carriers are nucleotide-based molecules and likely originated early in metabolism.
Sources: en.wikipedia.org
=== History of thalassemia === Rudolf Von Jaksch in 1889 first described "anaemia leucaemic infantum" as a form of chronic anemia in children which combined with an enlarged spleen, and abnormal size and shape of the red blood cells. His discovery was subsequently found to comprise a collection of different conditions. The first definitive identification of a thalassemia was in 1925 by Thomas Benton Cooley, an American pediatrician specialising in hematology and childhood anemias. Cooley noted similarities in symptoms of children in his care having Greek or Italian ancestry; he named it "erythroblastic anemia," but it became popularly known as Cooley's anemia (now termed beta thalassemia major). The term "thalassemia" was coined by George Whipple in 1932. The word "thalassemia" comes from the Greek word thalassa, which means "sea". The suffix "-emia" comes from the Greek word haima, which means "blood". The term was coined because the condition was strongly associated with people of Mediterranean descent. In 1948, Italian researchers established that the type of thalassemia which was prevalent in Italy was inherited in a recessive pattern.
=== Breast feeding === Pantoprazole has been found to pass through the breast milk. Additionally, in rodent cancer studies, pantoprazole has been shown to potentially cause tumor growth. The clinical relevance of the finding is unknown, but risks and benefits are recommended for consideration in determining the use of therapy for the mother and child.
relationship "a defining partnership of the 21st century", he also announced the removal of export control restrictions on several Indian companies, and concluded trade deals worth $10 billion, which are expected to create and/or support 50,000 jobs in the US.
Perineural cysts were first described by Dr. Isadore Tarlov in 1938. While conducting anatomical dissections of 30 human cadavers to study the filum terminale and lower spinal nerve roots, Tarlov identified cystic lesions on the S2 to S5 sacral nerve roots in five specimens, ranging in size from a pinhead to approximately 2 cm. He also reported degenerative changes in the nerve fibers, ganglion cells, and disintegration of myelin sheaths. These observations were published in a paper titled "Perineurial Cysts of the Spinal Nerve Roots (1938)", in which he suggested the possible clinical relevance of the cysts, stating: "One wonders whether they may not be responsible for the discomfort in certain cases of sciatica or nerve root pains, in which any other pathologic basis has been excluded. This awaits further studies with clinical and pathologic correlations." In 1948, Tarlov reported the first clinical case linking sacral perineural cysts to sciatic pain, establishing their potential as a treatable cause of radiculopathy. He described a 42-year-old woman who developed persistent right-sided sciatica following a fall. Although a herniated intervertebral disc was initially diagnosed, surgical exploration revealed a perineural cyst arising from the right S2 sacral nerve root, located under the posterior arch of the sacrum. The lesion was excised along with part of the dorsal root and ganglion. Postoperatively, the patient experienced significant improvement in motor function, pain, and sensation, without complications.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
The peptide backbone and its fatty acid side chain are susceptible to degradation at elevated temperatures. Refrigeration slows hydrolysis, oxidation, and aggregation processes. Labeled storage ranges reflect stability data generated under defined conditions.